Exicure, Inc.

NasdaqCM:XCUR Rapporto sulle azioni

Cap. di mercato: US$5.8m

Exicure Performance dei guadagni passati

Il passato criteri di controllo 0/6

Exicure has been growing earnings at an average annual rate of 14.9%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 12.5% per year.

Informazioni chiave

14.9%

Tasso di crescita degli utili

29.8%

Tasso di crescita dell'EPS

Biotechs Crescita del settore17.0%
Tasso di crescita dei ricavi12.5%
Rendimento del capitale proprio-506.6%
Margine netto-1,634.4%
Ultimo aggiornamento sui guadagni30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Little Excitement Around Exicure, Inc.'s (NASDAQ:XCUR) Revenues As Shares Take 25% Pounding

Aug 29
Little Excitement Around Exicure, Inc.'s (NASDAQ:XCUR) Revenues As Shares Take 25% Pounding

Exicure to get $5.4M equity financing, reduce workforce & end R&D, preclinical activities

Sep 26

Exicure Q2 GAAP loss per share narrows, revenue up

Aug 15

Exicure regains compliance with Nasdaq's minimum bid price requirement

Jul 20

Exicure slides 31% as it implements reverse-stock-split to get back Nasdaq compliance

Jun 29

Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

Aug 25
Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

Mar 10
Does Exicure (NASDAQ:XCUR) Have A Healthy Balance Sheet?

Ripartizione dei ricavi e delle spese

Come Exicure guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

NasdaqCM:XCUR Ricavi, spese e utili (USD Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Jun 241-860
31 Mar 241-13110
31 Dec 230-17130
30 Sep 23223130
30 Jun 23243130
31 Mar 23261110
31 Dec 2229-3110
30 Sep 229-35130
30 Jun 223-53130
31 Mar 221-60130
31 Dec 210-64130
30 Sep 21-2-63120
30 Jun 214-48110
31 Mar 218-38100
31 Dec 2017-25100
30 Sep 2017-2290
30 Jun 2015-1990
31 Mar 2010-2090
31 Dec 191-2690
30 Sep 191-2180
30 Jun 191-2180
31 Mar 190-2280
31 Dec 180-2280
30 Sep 182-2180
30 Jun 185-1880
31 Mar 187-1480
31 Dec 1710-1170
30 Sep 178-1360
30 Jun 176-1550
31 Mar 173-1640
31 Dec 161-1740
31 Dec 152-650

Guadagni di qualità: XCUR is currently unprofitable.

Margine di profitto in crescita: XCUR is currently unprofitable.


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: XCUR is unprofitable, but has reduced losses over the past 5 years at a rate of 14.9% per year.

Accelerare la crescita: Unable to compare XCUR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Guadagni vs Settore: XCUR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Rendimento del capitale proprio

ROE elevato: XCUR has a negative Return on Equity (-506.63%), as it is currently unprofitable.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate